Clinical Trials Browser

INDUSTRY × Injections × Breast × Clear all

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Phase 3 Recruiting

HER2-positive Breast Cancer

NCT07497386 2026-03-27

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Phase 2 Not yet recruiting

Unresectable Locally Recurrent Breast Cancer

NCT06765590 2026-03-09

Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

Phase NA Recruiting

Breast Neoplasms

NCT07208149 2026-02-12

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

NCT07196774 2026-01-30

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

Phase 3 Recruiting

Early-stage or Locally Advanced HER2-positive Breast Cancer

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT07130383 2025-11-18

A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

Phase 2 Recruiting

BreastOther solid neoplasm

Advanced Breast Cancer

NCT05634954 2025-10-23

Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT06449027 2025-10-01

Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Phase 3 Active not recruiting

Breast Cancer Subjects

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Phase 3 Recruiting

Breast Neoplasms

NCT07169994 2025-09-12

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06198751 2025-08-19

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT07008976 2025-08-14

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT07003074 2025-06-25

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Phase 2 Active not recruiting

Breast Neoplasms

NCT06948539 2025-04-29

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

Phase 1 Not yet recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms

NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Phase 3 Not yet recruiting

Breast Neoplasms

NCT03936933 2025-02-17

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

Phase 3 Terminated

Breast Neoplasms

NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Phase 1 Terminated

3 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

NCT06143553 2024-11-29

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT06452706 2024-11-19

The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06685796 2024-11-13

A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

Phase 2 Recruiting

Advanced Triple-Negative Breast Cancer

NCT05830097 2024-08-26

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

NCT06561607 2024-08-20

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06389006 2024-05-23

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06202261 2024-03-12

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT06115902 2023-11-29

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT05755048 2023-09-01

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT05845138 2023-08-01

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Phase 1/2 Unknown

Breast Neoplasms

NCT05110170 2023-05-16

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Phase 3 Completed

Breast Neoplasms

NCT04382352 2023-03-24

B002-101

Phase 1 Completed

Breast Neoplasms

NCT04924699 2023-03-17

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2/3 Unknown

Breast Neoplasms

NCT05765357 2023-03-13

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT05753865 2023-03-03

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Phase 3 Unknown

Advanced Breast Cancer

NCT05471648 2023-01-26

A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers

Phase 1 Completed

Breast Neoplasms

NCT04405505 2020-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Phase 3 Unknown

Triple Negative Breast Neoplasms

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Phase 1 Completed

BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT04185649 2019-12-04

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Phase 3 Unknown

HER2-positive Advanced Breast Cancer

NCT01479244 2017-02-27

PRESENT

Phase 3 Completed

Breast Neoplasms

NCT02154139 2016-02-17

Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"

651 enrolled 12 charts

Breast Neoplasms

NCT00918281 2014-06-09

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

Phase 2 Completed

70 enrolled 9 charts

BreastGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Sarcoma

NCT00041808 2005-06-24

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

Phase 1/2 Completed

BreastDermatologicGastrointestinalSarcomaThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Gastrointestinal Stromal Tumors